Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -127.12% is 15% below its 5-year average of -110.17%, near the high end of its 5-year range (-313.47%–-52.14%).
29.27% above its 12-month average of -179.73%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -313.47%.
EBITDA MARGIN
-127.12%
EBITDA MARGIN AVG TTM
-179.73%
EBITDA MARGIN AVG 3Y
-129.40%
EBITDA MARGIN AVG 5Y
-110.17%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+29.27%
CURRENT VS 3Y AVG
+1.76%
CURRENT VS 5Y AVG
-15.39%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Elutia Inc
Market Cap
$35.82M
EBITDA Margin
-127.12%
TTM Avg
-179.73%
3Y Avg
-129.40%
5Y Avg
-110.17%
Market Cap
$36.32M
EBITDA Margin
-136.01%
TTM Avg
-1016.71%
3Y Avg
-1237.80%
5Y Avg
-1237.80%
Market Cap
$36.64M
EBITDA Margin
-6.58%
TTM Avg
-1.77%
3Y Avg
-0.14%
5Y Avg
1.64%
Market Cap
$34.44M
EBITDA Margin
-7905.63%
TTM Avg
-7905.63%
3Y Avg
-7905.63%
5Y Avg
-7905.63%
Market Cap
$37.81M
EBITDA Margin
-1929.22%
TTM Avg
-1308.49%
3Y Avg
-1783.80%
5Y Avg
-1343.37%
Market Cap
$38.60M
EBITDA Margin
6.14%
TTM Avg
3.48%
3Y Avg
3.86%
5Y Avg
5.21%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Elutia Inc (ELUT) | $35.82M | -127.12% | -179.73% | -129.40% | -110.17% |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.32M | -136.01% | -1016.71% | -1237.80% | -1237.80% |
| BriaCell Therapeutics Corp. (BCTX)vs › | $36.45M | N/A | N/A | N/A | N/A |
| Accuray Incorporated (ARAY)vs › | $36.64M | -6.58% | -1.77% | -0.14% | 1.64% |
| DocGo Inc. (DCGO)vs › | $36.70M | -22.81% | -7.79% | -0.80% | -0.97% |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.44M | -7905.63% | -7905.63% | -7905.63% | -7905.63% |
| Edesa Biotech, Inc. (EDSA)vs › | $37.81M | -1929.22% | -1308.49% | -1783.80% | -1343.37% |
| HeartBeam, Inc. (BEAT)vs › | $33.32M | 31.08% | 27.03% | 24.58% | 21.46% |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.60M | 6.14% | 3.48% | 3.86% | 5.21% |
| Incannex Healthcare Limited (IXHL)vs › | $38.82M | -27375.58% | -138216.12% | -92142.37% | -55460.65% |
Gross Margin
57.8%
EBITDA Margin
-127.1%
Operating Margin
-149.8%
Net Margin
426.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -313.47% |
| 2026-03-31 | -173.80% |
| 2025-12-31 | -158.79% |
| 2025-09-30 | -109.15% |
| 2025-06-30 | -143.43% |
| 2025-03-31 | -116.98% |
| 2024-12-31 | -138.42% |
| 2024-09-30 | -158.19% |
| 2024-06-30 | -121.57% |
| 2024-03-31 | -113.76% |
| 2023-12-31 | -129.60% |
| 2023-09-30 | -104.75% |
| 2023-06-30 | -84.32% |
| 2023-03-31 | -115.64% |
| 2022-12-31 | -62.42% |
| 2022-09-30 | -137.36% |
| 2022-06-30 | -57.35% |
| 2022-03-31 | -52.14% |
| 2021-12-31 | -62.88% |
| 2021-09-30 | -52.63% |
